Type 2 Diabetes (T2D) Clinical Trials

Find Type 2 Diabetes (T2D) Clinical Trials Near You

Rare and Atypical Diabetes Network

Status: Recruiting
Location: See all (13) locations...
Study Type: Observational
SUMMARY

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

⁃ The following criteria or phenotypes will be considered for suspecting atypical participants:

• Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese

• Mendelian pattern, especially with early onset (\<18 years old)

• Syndromic (multiple systems involved)

• Lipodystrophic

• Extremes of BMI

• Mitochondrial characteristics (e.g., myopathy, hearing deficits)

• Non-progressive

• Rapidly progressive (fulminant)

• Low insulin requirements (\<0.5 u/kg/day)

• Cyclical hyperglycemia with periods of remission

• Lean persons with polycystic ovarian syndrome (PCOS)

• History of gestational diabetes (GDM) when lean

• Lean insulin-resistant persons

• If islet autoantibodies and beta-cell function parameters have been measured (where A = islet cell autoantibodies, B = beta-cell function):

⁃ oA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)

Locations
United States
Colorado
University of Colorado- Denver
RECRUITING
Aurora
Illinois
University of Chicago
RECRUITING
Chicago
Indiana
Indiana University
RECRUITING
Indianapolis
Massachusetts
Massachusetts General Hospital (MGH)
RECRUITING
Boston
Maryland
University of Maryland
RECRUITING
Baltimore
Michigan
University of Michigan
RECRUITING
Ann Arbor
Missouri
Washington University in St. Louis
RECRUITING
St Louis
North Carolina
University of North Carolina at Chapel Hill
RECRUITING
Chapel Hill
New York
SUNY Downstate Health Sciences University
RECRUITING
Brooklyn
Columbia University
RECRUITING
New York
Tennessee
Vanderbilt University
RECRUITING
Nashville
Texas
Baylor College of Medicine
RECRUITING
Houston
Washington
University of Washington
RECRUITING
Seattle
Contact Information
Primary
Jeffrey Krischer, PhD
contact@atypicaldiabetesnetwork.org
813-396-9501
Time Frame
Start Date: 2020-09-30
Estimated Completion Date: 2030-09
Participants
Target number of participants: 2000
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leads: University of South Florida

This content was sourced from clinicaltrials.gov